CoChat
Sign Up
Cited by 165Lysosomal Storage Disorders ResearchGlycogen Storage Diseases and MyoclonusRNA Interference and Gene Delivery

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates

Open access
Zhu, Xuling, Yin, Ling, Theisen, Matt, Zhuo, Jenny, Siddiqui, Summar, Levy, Becca, Presnyak, Vladimir, Frassetto, Andrea, Milton, Jaclyn, Salerno, Timothy, Benenato, Kerry E., Milano, Joe, Lynn, Andy, Sabnis, Staci, Burke, Kristine, Besin, Gilles, Lukacs, Christine M., Guey, Lin T., Finn, Patrick F., Martini, Paolo G.V.·2019·The American Journal of Human Genetics
DOI 10.1016/j.ajhg.2019.02.003PMC PMC6451694
Open this paper in CoChat — free accountOpen PDF

Abstract

Fabry disease is an X-linked lysosomal storage disease caused by loss of alpha galactosidase A (α-Gal A) activity and is characterized by progressive accumulation of globotriaosylceramide and its analogs in all cells and tissues. Although enzyme replacement therapy (ERT) is considered standard of care, the long-term effects of ERT on renal and cardiac manifestations remain uncertain and thus novel therapies are desirable. We herein report preclinical studies evaluating systemic messenger RNA (mRNA) encoding human α-Gal A in wild-type (WT) mice, α-Gal A-deficient mice, and WT non-human primates (NHPs). The pharmacokinetics and distribution of h-α-Gal A mRNA encoded protein in WT mice demonstrated prolonged half-lives of α-Gal A in tissues and plasma. Single intravenous administration of h-α-Gal A mRNA to Gla-deficient mice showed dose-dependent protein activity and substrate reduction. Moreover, long duration (up to 6 weeks) of substrate reductions in tissues and plasma were observed after a single injection. Furthermore, repeat i.v. administration of h-α-Gal A mRNA showed a sustained pharmacodynamic response and efficacy in Fabry mice model. Lastly, multiple administrations to non-human primates confirmed safety and translatability. Taken together, these studies across species demonstrate preclinical proof-of-concept of systemic mRNA therapy for the treatment of Fabry disease and this approach may be useful for other lysosomal storage disorders.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ajhg.2019.02.003

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 51 references

Cited by

Sorted by citations

Items 101–165 of 165

Related

See all

Metadata

Authors
Zhu, X., Yin, L., Theisen, M., Zhuo, J., Siddiqui, S., Levy, B., Presnyak, V., Frassetto, A., Milton, J., Salerno, T., Benenato, K. E., Milano, J., Lynn, A., Sabnis, S., Burke, K., Besin, G., Lukacs, C. M., Guey, L. T., Finn, P. F., & Martini, P. G. V.
Corresponding author
Martini, Paolo G.V.
ORCID
Venue
The American Journal of Human Genetics
Publisher
Elsevier BV
Published
2019-04
Volume
104
Issue
4
Pages
625-637
ISSN
0002-9297 (ISSN-L)
DOI
10.1016/j.ajhg.2019.02.003
PMC
PMC6451694
OpenAlex
W2921621642
Cited by
165
References
51
Citations by year
2026: 12 · 2025: 30 · 2024: 26 · 2023: 20 · 2022: 32 · 2021: 23 · 2020: 14 · 2019: 8
FWCI
13.16
Type
journal article
Language
en
Open access
Licence
Locations
  • The American Journal of Human Genetics (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Moderna
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
Fabry disease, alpha-galactosidase A, globotriaosylceramide, lysosomal storage disease, enzyme replacement therapy, pharmacokinetics, pharmacodynamics, non-human primates, substrate reduction, X-linked disorders
MeSH terms
alpha-Galactosidase, Fabry Disease, Animals, Disease Models, Animal, Endocytosis, Humans, Lipids, Lysosomes, Macaca fascicularis, Male, RNA, Messenger, Tissue Distribution, Trihexosylceramides, Genetic Therapy, Mice, Knockout, Mice, Enzyme Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review